AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19043378 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (2 mg x kg(‐1) x h(‐1); group A; n=27)
Number of subjects: 54
Study 19043378 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline as placebo (group B; n=27)
Number of subjects: 54
Study 15530134 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-tolterodine with antacid
Number of subjects: 0
Study 15530134 — intervention group
Group type: COMPARATOR
Intervention: ER-tolterodine without antacid
Number of subjects: 0
Study 15530134 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-oxybutynin with antacid
Number of subjects: 0
Study 15530134 — intervention group
Group type: COMPARATOR
Intervention: ER-oxybutynin without antacid
Number of subjects: 0
Study 11676100 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to car ads
Number of subjects: 0
Study 11676100 — intervention group
Group type: COMPARATOR
Intervention: Attention to skin-care ads
Number of subjects: 0
Study 9558750 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with n-3 PUFA
Number of subjects: 0
Study 7934985 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose alone (GLUC) 4.1 mg/kg/min, n = 8
Number of subjects: 18
Study 7934985 — intervention group
Group type: COMPARATOR
Intervention: Glucose with amino acids (TPN) 275 mg N/kg/d, n = 10
Number of subjects: 18
Study 3300045 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (2 X 200 mg for 10 days)
Number of subjects: 40
Study 3300045 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (2 X 160 mg Trimethoprim + 800 mg Sulphamethoxazole for 10 days)
Number of subjects: 40
Study 31310991 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling and referral for physical activity programs group (CRG)
Number of subjects: 142
Study 31310991 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 142
Study 31310991 — intervention group
Group type: COMPARATOR
Intervention: Physician-based counseling group
Number of subjects: 142
Study 30098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (50 µg/kg)
Number of subjects: 150
Study 30098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled levosimendan (24 µg/kg)
Number of subjects: 150
Study 30098861 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 150
Study 26563405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme in addition to high-dose methylprednisolone (HDMP)
Number of subjects: 0
Study 26563405 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid therapy alone (HDMP)
Number of subjects: 0
Study 24326731 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (heart-rate reserve 40-60%) for 8 weeks
Number of subjects: 77
Study 23149528 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vital sign intervention (n = 26)
Number of subjects: 2304
Study 23149528 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 2304
Study 20843662 — intervention group
Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 21
Study 20843662 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapy)
Number of subjects: 21
Study 17944896 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 66
Study 17944896 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening bright light
Number of subjects: 66
Study 17944896 — intervention group
Group type: EXPERIMENTAL
Intervention: All-day bright light
Number of subjects: 66
Study 17944896 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard light
Number of subjects: 66
Study 16357191 — intervention group
Group type: EXPERIMENTAL
Intervention: Very well done meat consumption (>10 g/d)
Number of subjects: 29361
Study 16357191 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of PhIP intake
Number of subjects: 29361
Study 11241462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) given in different three-dose schedules
Number of subjects: 5
Study 11241462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) given at 18 months
Number of subjects: 5
Study 11241462 — intervention group
Group type: COMPARATOR
Intervention: Control group immunized with the current schedule (first dose at 6 months)
Number of subjects: 5
Study 11241462 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibodies present at the time of the first dose
Number of subjects: 5
Study 9215242 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 gm MSG
Number of subjects: 61
Study 9215242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 7966058 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 126
Study 7966058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 2960474 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (6.5 X 10(‐5)‐6.5 X 10(‐3)M)
Number of subjects: 8
Study 2960474 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 31133144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (250 mg twice daily) with topical 3% tranexamic acid (twice daily)
Number of subjects: 100
Study 31133144 — intervention group
Group type: COMPARATOR
Intervention: Oral tranexamic acid (250 mg twice daily) with topical 20% azelaic acid (daily)
Number of subjects: 100
Study 28096239 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) for 90 minutes
Number of subjects: 40
Study 28096239 — intervention group
Group type: COMPARATOR
Intervention: Incubator care (control)
Number of subjects: 40
Study 26075935 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM-based education for 3 months
Number of subjects: 166
Study 26075935 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional (didactic) method
Number of subjects: 166
Study 26075935 — intervention group
Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 166
Study 22738415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-facilitated angina management programme
Number of subjects: 14
Study 22738415 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study 21868616 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid levels (measured in mg/dl)
Number of subjects: 5827
Study 21868616 — intervention group
Group type: COMPARATOR
Intervention: Uric acid ≤8.2 mg/dl
Number of subjects: 5827
Study 19938160 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype
Number of subjects: 250
Study 16998619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 55
Study 16998619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 55
Study 16998619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris-acryl gelatin microspheres
Number of subjects: 100
Study 15297582 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl alcohol (PVA) particles
Number of subjects: 100
Study 11115705 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV + Hib
Number of subjects: 320
Study 11115705 — intervention group
Group type: COMPARATOR
Intervention: DTPw-IPV/Hib + HBV
Number of subjects: 320
Study 9437182 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh: 0.1, 0.8, and 4.0 micrograms/min)
Number of subjects: 20
Study 9437182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP: 0.5, 2.5, and 10 micrograms/min)
Number of subjects: 20
Study 9437182 — intervention group
Group type: COMPARATOR
Intervention: Control group (NC)
Number of subjects: 20
Study 8101194 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg once daily)
Number of subjects: 16
Study 8101194 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 16
Study 8101194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31128381 — intervention group
Group type: COMPARATOR
Intervention: EPC (Enhanced Primary Care)
Number of subjects: 638
Study 31128381 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC+C (Enhanced Primary Care plus Individualized Coaching)
Number of subjects: 638
Study 31128381 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC and EPC+C
Number of subjects: 638
Study 31128381 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC+C
Number of subjects: 638
Study 29799827 — intervention group
Group type: EXPERIMENTAL
Intervention: HARDL (HA gel with lidocaine)
Number of subjects: 162
Study 29799827 — intervention group
Group type: COMPARATOR
Intervention: HAJUP (HA gel without lidocaine)
Number of subjects: 162
Study 29799827 — intervention group
Group type: EXPERIMENTAL
Intervention: HARDL
Number of subjects: 162
Study 29799827 — intervention group
Group type: COMPARATOR
Intervention: HAJUP
Number of subjects: 162
Study 27115157 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g/day for 8 weeks)
Number of subjects: 34
Study 27115157 — intervention group
Group type: COMPARATOR
Intervention: Medium-chain triglycerides (MCT) oil (6 g/day for 8 weeks)
Number of subjects: 34
Study 25273342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks)
Number of subjects: 494
Study 25273342 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 494
Study 25273342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 494
Study 22447880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMCs) transendocardial injection (100 million BMCs)
Number of subjects: 92
Study 22447880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 20131246 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg)
Number of subjects: 30
Study 20131246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19115423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus taper
Number of subjects: 86
Study 19115423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group support (GS) plus taper
Number of subjects: 86
Study 19115423 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (taper only) plus physician counselling
Number of subjects: 86
Study 15828586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisin
Number of subjects: 165
Study 15828586 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 165
Study 15828586 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxin-pyrimethamin
Number of subjects: 165
Study 15828586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisin (second cure)
Number of subjects: 165
Study 12597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifenthrin 100 mg/m2
Number of subjects: 5
Study 12597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifenthrin 200 mg/m2
Number of subjects: 5
Study 12597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifenthrin 50 mg/m2
Number of subjects: 5
Study 12597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifenthrin 25 mg/m2
Number of subjects: 5
Study 12597653 — intervention group
Group type: COMPARATOR
Intervention: Malathion 2 g/m2
Number of subjects: 5
Study 12597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifenthrin 25 mg/m2 and 50 mg/m2
Number of subjects: 5
Study 12597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy of bifenthrin
Number of subjects: 5
Study 10469685 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-HP
Number of subjects: 31
Study 10469685 — intervention group
Group type: COMPARATOR
Intervention: FSH-HP + rhLH
Number of subjects: 31
Study 8737435 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service training programme for medical assistants
Number of subjects: 0
Study 1906808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 702
Study 1906808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine with levodopa (combination therapy)
Number of subjects: 702
Study 1906808 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (control group)
Number of subjects: 702
Study 6352661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 50
Study 6352661 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin/Tobramycin
Number of subjects: 50
Study 27241348 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Implemented TEACCH for Toddlers (FITT)
Number of subjects: 50
Study 27241348 — intervention group
Group type: COMPARATOR
Intervention: Community services as usual
Number of subjects: 50
Study 28281050 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model-guided (RMG) antiemetic prophylaxis
Number of subjects: 324
Study 28281050 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice (PC) antiemetic prophylaxis
Number of subjects: 324
Study 27164480 — intervention group
Group type: EXPERIMENTAL
Intervention: GAME (Goals - Activity - Motor Enrichment)
Number of subjects: 30
Study 27164480 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 24948586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan 200 mg/m(2) plus salvage ASCT
Number of subjects: 174
Study 24948586 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide (400mg/m(2) per week for 12 weeks)
Number of subjects: 174
Study 24948586 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD induction therapy
Number of subjects: 174
Study 24948586 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage ASCT
Number of subjects: 174
Study 24948586 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 174
Study 22101219 — intervention group
Group type: EXPERIMENTAL
Intervention: Study agent
Number of subjects: 94
Study 22101219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 19730965 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Tension (AT)
Number of subjects: 98
Study 19730965 — intervention group
Group type: COMPARATOR
Intervention: No Applied Tension (Control)
Number of subjects: 98
Study 17404152 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (gemcitibine + ifosfamide + cisplatin)
Number of subjects: 485
Study 17404152 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (225 mg/m(2) over 3 h every 3 weeks)
Number of subjects: 485
Study 14660219 — intervention group
Group type: COMPARATOR
Intervention: Shorts (S)
Number of subjects: 24
Study 11176403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical electromotive oxybutynin
Number of subjects: 10
Study 11176403 — intervention group
Group type: COMPARATOR
Intervention: Intravesical passive diffusion oxybutynin
Number of subjects: 10
Study 11176403 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 10
Study 9572635 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of prednisolone for the first six months, followed by lower doses thereafter
Number of subjects: 24
Study 9572635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose glucocorticoid schedule after initial high doses
Number of subjects: 24
Study 8046559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol mouthrinse
Number of subjects: 133
Study 8046559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol mouthrinse
Number of subjects: 133
Study 8046559 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control mouthrinse
Number of subjects: 133
Study 2657953 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraghurt tablets (freeze‐dried culture of Streptococcus faecium)
Number of subjects: 54
Study 2657953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31003114 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based self-help intervention
Number of subjects: 110
Study 31003114 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 110
Study 28801112 — intervention group
Group type: EXPERIMENTAL
Intervention: Coracoclavicular ligament reconstruction using autologous gracilis tendon with suture anchor
Number of subjects: 42
Study 28801112 — intervention group
Group type: COMPARATOR
Intervention: Clavicular hook plate
Number of subjects: 42
Study 25193602 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling intervention (contacted by telephone or in clinic up to 4 months post-delivery)
Number of subjects: 120
Study 25193602 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 120
Study 25193602 — intervention group
Group type: COMPARATOR
Intervention: Control group (negative attitudes)
Number of subjects: 120
Study 22406043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 ng/mL
Number of subjects: 48
Study 22406043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 ng/mL
Number of subjects: 48
Study 22406043 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0.4 ng/mL
Number of subjects: 48
Study 21271601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 50
Study 21271601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18652265 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (SE, Kuraray) applied to dentin surfaces prepared with 600-grit SiC abrasive paper
Number of subjects: 50
Study 18652265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed tungsten carbide bur with Clearfil SE Bond (SE, Kuraray)
Number of subjects: 50
Study 18652265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed diamond bur with Clearfil S3 Bond (S3, Kuraray)
Number of subjects: 50
Study 17063980 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg (Merck S.A. Indústrias Químicas)
Number of subjects: 24
Study 17063980 — intervention group
Group type: COMPARATOR
Intervention: Movatec 15 mg (control formulation)
Number of subjects: 24
Study 14670782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone as adjuvant therapy
Number of subjects: 598
Study 14670782 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 598
Study 10966840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg FCHG49 glucosamine HCl, 800 mg TRH122 low molecular weight sodium chondroitin sulfate and 152 mg manganese ascorbate twice daily (Cosamin DS)
Number of subjects: 93
Study 10966840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 8867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 27
Study 8867164 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar injection
Number of subjects: 27
Study 1460202 — intervention group
Group type: EXPERIMENTAL
Intervention: Greer Pen (GP)
Number of subjects: 20
Study 1460202 — intervention group
Group type: EXPERIMENTAL
Intervention: Greer DermaPIK (DP)
Number of subjects: 20
Study 1460202 — intervention group
Group type: EXPERIMENTAL
Intervention: Center Multi‐Test (MT)
Number of subjects: 20
Study 1460202 — intervention group
Group type: EXPERIMENTAL
Intervention: Morrow Brown needle (MB)
Number of subjects: 20
Study 1460202 — intervention group
Group type: COMPARATOR
Intervention: Glycerosaline control
Number of subjects: 20
Study 6422735 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus lidoflazine (L)
Number of subjects: 29
Study 6422735 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus placebo (P)
Number of subjects: 29
Study 6422735 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus lidoflazine (L) after crossover
Number of subjects: 29
Study 6422735 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus placebo (P) after crossover
Number of subjects: 29
Study 6422735 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Propranolol + Lidoflazine)
Number of subjects: 29
Study 29234941 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic group (LAG)
Number of subjects: 322
Study 29234941 — intervention group
Group type: COMPARATOR
Intervention: Open group
Number of subjects: 322
Study 26916239 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 16
Study 26916239 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 16
Study 25803256 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible regimen of daily risedronate (5 mg)
Number of subjects: 448
Study 25803256 — intervention group
Group type: COMPARATOR
Intervention: Fixed regimen of daily risedronate (5 mg)
Number of subjects: 448
Study 23899372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 23899372 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 20811320 — intervention group
Group type: EXPERIMENTAL
Intervention: FK778
Number of subjects: 0
Study 20811320 — intervention group
Group type: COMPARATOR
Intervention: Standard care (reduction of immunosuppression)
Number of subjects: 0
Study 18240234 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) alone
Number of subjects: 72
Study 18240234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azathioprine (AZA)
Number of subjects: 72
Study 18240234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulse cyclophosphamide (CYC)
Number of subjects: 72
Study 18240234 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 72
Study 18240234 — intervention group
Group type: COMPARATOR
Intervention: Low-dose corticosteroids (CS) therapy
Number of subjects: 72
Study 18240234 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid-related adverse events
Number of subjects: 72
Study 16376467 — intervention group
Group type: EXPERIMENTAL
Intervention: Men during hip lateral rotation
Number of subjects: 46
Study 16376467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip lateral rotation test
Number of subjects: 46
Study 12745095 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg IV)
Number of subjects: 100
Study 12745095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100